Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06196736
Other study ID # 9MW2821-2023-CP301
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date December 31, 2023
Est. completion date December 31, 2028

Study information

Verified date December 2023
Source Mabwell (Shanghai) Bioscience Co., Ltd.
Contact Dingwei Ye, Professor
Phone +8613701663571
Email fuscc2012@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 420
Est. completion date December 31, 2028
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form. 2. Male or female subjects aged 18 to 75 years (including 18 and 75 years). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histologically confirmed locally advanced or metastatic urothelial cancer, not amenable to resection with curative intent. 5. Subject must have received a platinum containing chemotherapy and PD-(L)1 inhibitor in the metastatic/locally advanced setting. If platinum and/or PD-(L)1 inhibitor was administered in the adjuvant/neoadjuvant setting subject must have progressed during treatment or within 12 months of completion. 6. Subject must have experienced radiographic progression during or after the last treatment regimen. 7. An archival tumor tissue sample or a fresh tissue sample should be provided. 8. Life expectancy of = 12 weeks. 9. Subjects must have measurable disease according to RECIST (version 1.1). 10. Adequate organ functions. 11. Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy. 12. Subjects are willing to follow study procedures. Exclusion Criteria: 1. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug, traditional Chinese medicine with anticancer indication within 14 days prior to the first dose of study drug, use of any investigational drug or device within 28 days prior to the first dose of study drug, received treatment of nectin-4 targeted ADC, received treatment of ADC with MMAE payload, received prior chemotherapy with all available study therapies in the control arm, any strong CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug. 2. Preexisting treatment related toxicity Grade = 2 (except alopecia and grade 2 endocrine system toxicity with stable replacement therapy). 3. Major surgery within 28 days prior to first dose of study drug. 4. Hemoglobin A1C (HbA1c) = 8%. 5. Preexisting peripheral neuropathy Grade = 2. 6. Any live vaccines within 28 days before first dose of study drug or during the study. 7. Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug. 8. Other severe or uncontrolled disease, i.e. severe respiratory system disease, thromboembolic events, active bleeding or active infection. 9. Central nervous system metastases. 10. History of another malignancy within 3 years before the first dose of study drug. Subjects with cured malignancies are allowed. 11. History of autoimmune disease requiring systemic treatment within 2 years before the first dose of study drug. 12. Has ocular conditions that may increase the risk of corneal epithelium damage. 13. Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness. 14. Uncontrolled tumor-related bone pain or spinal cord compression. Patients requiring pain medication must be on a stable regimen for at least 2 weeks before the first dose of study drug. 15. Pleural effusion, ascites or pericardial effusion with syptoms or needed drainage. 16. Condition or situation which may put the subject at significant risk.

Study Design


Intervention

Drug:
9MW2821
1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Chemotherapy
75mg/m^2 docetaxel by intravenous infusion or 175 mg/m^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Mabwell (Shanghai) Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival per Blinded Independent Central Review Time from the date of first randomization to the earliest date of documented disease progression per radiological evidence or death from any cause Up to 3 years
Primary Overall Survival Time from the date of randomization until the date of death from any cause Up to 3 years
Secondary Objective Response Rate per Blinded Independent Central Review and investigator The percentage of subjects who experience a best response of either CR or PR Up to 3 years
Secondary Duration of Response per Blinded Independent Central Review and investigator Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause Up to 3 years
Secondary Time to response per Blinded Independent Central Review and investigator Time from the date of randomization to the date of confirmed CR or PR Up to 3 years
Secondary Disease Control Rate per Blinded Independent Central Review and investigator Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD) Up to 3 years
Secondary Progression Free Survival per investigator Time from the date of first randomization to the earliest date of documented disease progression per radiological evidence or death from any cause Up to 3 years
Secondary Incidence of adverse events Up to 3 years
Secondary Incidence of Anti-Drug Antibody (ADA) Up to 3 years
Secondary Mean change from baseline in the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core quality-of-life questionnaire (QLQ-C30) Up to 3 years
Secondary Mean change from baseline in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS) Up to 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04603846 - A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma Phase 1
Active, not recruiting NCT00365157 - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Phase 1/Phase 2
Recruiting NCT01487915 - Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma Phase 2
Not yet recruiting NCT04064190 - Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Phase 2
Not yet recruiting NCT06079112 - 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer Phase 1/Phase 2
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT02735252 - PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer N/A
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Recruiting NCT05738161 - Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma Phase 1
Completed NCT00942331 - Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Phase 3
Not yet recruiting NCT05687721 - Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer Phase 1/Phase 2
Recruiting NCT04871334 - Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma Phase 1
Completed NCT02599324 - Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Phase 1/Phase 2
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1
Recruiting NCT05929235 - A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Phase 1
Recruiting NCT04856189 - Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma Phase 1/Phase 2